IntroductionCanada is plagued by an illicit market and oversupply while in the U.S. the allure has dimmed amid regulatory hurdles and a lack of timeline for federal legalization. In response, the largest cannabis companies in both countries are ramping up investments in Germany, the largest medical cannabis market in Europe, after the country decriminalized cannabis possession and small-scale home cultivation in April, making it easier for doctors to prescribe it. With only a few local companies licensed to grow marijuana, however, U.S. and Canadian MSOs and LPs are looking to capture a slice of the market by providing capital and exporting products to Germany. Below is how that burgeoning opportunity translates into the stock prices of the largest participants.Below are how the 5 constituents in the Canadian Cannabis LP Portfolio performed this week, in descending order, MTD and YTD.The munKNEE Canadian Cannabis LP Portfolio
- Aurora Cannabis Is Having a Good Year in 2024. Has It Turned Its Business Around?
- Aurora Receives Expanded Cultivation and Unique Research Licenses for German Facility
- Will the U.S. Election Help Give Tilray Brands and Canopy Growth a Year-End Boost?
- Tilray Receives First New Cannabis Cultivation License in Germany Under New Regulations
Below are how the 7 constituents in the American Cannabis MSO Portfolio performed this week, in descending order, MTD and YTD.The munKNEE American Cannabis MSO Portfolio
On average, the MSO Portfolio was up 0.1% this week, is up 3.2% MTD and is now up 15.4% YTD. Summary
More By This Author:Much Less Volatility Occurred In AI Stocks On Thursday
The AI/Tech Stock Selloff Is Overdone – It’s Time To Buy The Dip – Here’s Why
Almost All AI Stocks Declined Sharply On Wednesday – Here’s Why
